Inovio Pharmaceuticals, INC Schedule 13G passive stakes

Adage Capital Management, L.P. and associated entities have reported beneficial ownership of 4.00% of Inovio Pharmaceuticals, Inc. common stock, primarily through exercisable warrants.

RA Capital Management and its affiliates have reported beneficial ownership of 9.9% of Inovio Pharmaceuticals' common stock, primarily through RA Capital Healthcare Fund, L.P., which holds shares and warrants.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 10.3% in Inovio Pharmaceuticals as of June 30, 2026.

Vanguard Capital Management has disclosed a beneficial ownership of 5.05% of Inovio Pharmaceuticals Inc. common stock as of June 30, 2026.

Highbridge Capital Management LLC has increased its beneficial ownership of Inovio Pharmaceuticals, Inc. common stock to 8.2%, primarily through the exercise of warrants.

Adage Capital Management, L.P. has reported a beneficial ownership of 5.84% in Inovio Pharmaceuticals, Inc., including shares issuable upon warrant exercise.

FMR LLC, through its subsidiaries, reports beneficial ownership of 13.5% of Inovio Pharmaceuticals Inc. common stock as of March 31, 2026.

The Vanguard Group has reduced its beneficial ownership in Inovio Pharmaceuticals Inc. to 4.96% as of December 31, 2025, triggering an amended Schedule 13G filing.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in INOVIO Pharmaceuticals, Inc., primarily through shared voting and dispositive power.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a beneficial ownership of 14.8% of INOVIO PHARMACEUTICALS INC's common stock as of November 28, 2025.

Alyeska Investment Group, L.P. and its affiliates have reported a beneficial ownership of 7.53% in INOVIO PHARMACEUTICALS, comprising 4,000,000 shares through warrants.

Janus Henderson Group plc and its affiliate have reported a significant beneficial ownership stake of 6.2% in INOVIO PHARMACEUTICALS, INC. common stock.

Deep Track Capital, LP and affiliates reported a passive 2.41% beneficial ownership stake in INOVIO Pharmaceuticals, Inc. as of September 30, 2025.

Adage Capital Management, L.P. and its principals have reported a 9.99% beneficial ownership stake in Inovio Pharmaceuticals, Inc., including shares from warrant exercises.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 1.5% of INOVIO PHARMACEUTICALS INC's common stock as of June 30, 2025.

Stonepine Capital Management, LLC and its affiliated entities have filed an amended Schedule 13G, disclosing a beneficial ownership of 3.8% of Inovio Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

The Vanguard Group has reported a 5.53% beneficial ownership stake in Inovio Pharmaceuticals Inc., primarily for investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.3% beneficial ownership stake in INOVIO PHARMACEUTICALS INC as of March 31, 2025.

Highbridge Capital Management, LLC has reported a significant beneficial ownership stake of 9.2% in Inovio Pharmaceuticals, Inc., primarily through shares issuable upon warrant exercise.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.3% beneficial ownership stake in INOVIO PHARMACEUTICALS INC as of December 31, 2024.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.64% passive beneficial ownership stake in Inovio Pharmaceuticals Inc. as of December 31, 2024.